Navigation Links
Diabetes Advocates Call For National Strategy, Leadership to Reduce Diabetes and Advance Detection and Treatment
Date:7/13/2009

the Triple Bottom Line: a commitment to social responsibility to employees and customers, environmental soundness and economic success. With headquarters in Denmark, Novo Nordisk employs more than 27,550 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For global information, visit novonordisk.com; for United States information, visit novonordisk-us.com.


'/>"/>
SOURCE National Changing Diabetes Program
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Adverse housing conditions contribute to diabetes risk
2. RAND finds cases of undiagnosed diabetes drop sharply
3. UCLA researchers identify markers that may predict diabetes in still-healthy people
4. Diabetes appears to increase risk of death for patients with acute coronary syndromes
5. Discovery of sugar sensor in intestine could benefit diabetes
6. Despite overeating, morbidly obese mice gain protection against diabetes
7. Heart Attack Boosts Diabetes Risk
8. Obesity Doesnt Always Equal Diabetes
9. Sugary Sodas High in Diabetes-Linked Compound
10. Treating diabetes during pregnancy can break link to childhood obesity
11. Treating Diabetes During Pregnancy Could Lead to Thinner Kids

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...rgetIndividualsintheRecommendedPriorityGroups ,...TheDepartmentofHealthannouncedtodaytheywillconduct...ealthCentersinDelaware,Lancaster,andLehighcounties...ewillbeadministeredforfreetoindividualsintherecomm...vaccine.Thedepartmentasksthatonlyindividualsinthef...
(Date:11/23/2009)... compounds appears to cause oxidative DNA damage a... a new study published online November 23 in the ...hough biomethylation was once believed to detoxify...ts toxicity and potentially its carcinogenicity. ...in oxidative DNA damage in mice, Michael P. Waalke...
(Date:11/23/2009)...e children who don,t access health care from the s...ficantly more likely to have unmet health care nee...y published in the journal Pediatrics . , Stud...ng and delivery of quality health care for childre...licy debates about health insurance reform, much o...
(Date:11/23/2009)...-- A first-of-its-kind consensus statement on diab...als of Surgery . The report illustrates the findin... -- Diabetes Surgery Summit (DSS) -- where an inte...ical experts agreed on a set of evidence-based gui...e use and study of gastrointestinal surgery to tre...
(Date:11/23/2009)...tting chemo deal with insomnia, study shows , ...ia and sleep disorders affect more than three-quar... rate nearly three times higher than that of the g...blem is more common in younger patients and in tho...f Rochester Medical Center researchers, who assess...
Breaking Medicine News(10 mins):Health News:Pennsylvania Department of Health Announces Additional H1N1 Vaccination Clinics in Delaware, Lancaster, Lehigh Counties 2Health News:Children who lack continuity with a regular health care provider miss needed services 2Health News:Children who lack continuity with a regular health care provider miss needed services 3Health News:Diabetes surgery summit consensus lays foundation for new field of medicine 2Health News:Diabetes surgery summit consensus lays foundation for new field of medicine 3Health News:Diabetes surgery summit consensus lays foundation for new field of medicine 4Health News:Diabetes surgery summit consensus lays foundation for new field of medicine 5
... CareTech Solutions, an information,technology (I...itals and,health systems, announced today that it ...IT Outsourcing (Extensive) market segment, as rank...ons become more challenging, healthcare providers ...
...n reach immune cells in just 4 hours , , T... male-to-female transmission of HIV -- in which th... reach immune cells in just four hours -- has been...ntercourse, because the large HIV virus couldn,t p...
...16 /PRNewswire-Asia-FirstCall/ -- China Sky One,Me...ny") (Nasdaq: CSKI ), a,leading fully integrated...,drugs in the People,s Republic of China ("PRC"), ...rugs: Sodium Cromoglicate,Eye Drops for the treatm...
...ec. 16 White Mountains Re Ltd., the reinsurance u...: WTM ), announced today that Chuck Chokel, Chie...rk at the end of the year. He has agreed to remai... has filled many roles within our ever changing or...
... MED3OOO, Inc., a national healthcare management, ...illing company, has been able to help the City of ...at was not being billed to insurance companies. , ...nd collect revenues from insurance carriers for am...
... CeloNova BioSciences, Inc., announced,today that...he U.S. Food and,Drug Administration (FDA) for Emb...dicated for the treatment of hypervascularized tum...al sales of,Embozene(TM) Microspheres will begin i...
Other Medicine News:Health News:CareTech Solutions Named 'Best in KLAS' for Extensive IT Outsourcing Services 2Health News:HIV Can Penetrate a Woman's Healthy Genital Skin 2Health News:China Sky One Medical, Inc. Obtains Production Rights for Two Additional Drugs 2Health News:China Sky One Medical, Inc. Obtains Production Rights for Two Additional Drugs 3Health News:White Mountains Re Announces Management Changes -- Chokel to Retire and Remain Risk Advisor at WTM 2Health News:White Mountains Re Announces Management Changes -- Chokel to Retire and Remain Risk Advisor at WTM 3Health News:White Mountains Re Announces Management Changes -- Chokel to Retire and Remain Risk Advisor at WTM 4Health News:City of Newark, Ohio Increases Safety Services with EMS Revenue Recovered by MED3OOO EMS Billing 2Health News:City of Newark, Ohio Increases Safety Services with EMS Revenue Recovered by MED3OOO EMS Billing 3Health News:CeloNova BioSciences Receives FDA Market Approval for Embozene(TM) Color-Advanced Microspheres Embolization Platform 2Health News:CeloNova BioSciences Receives FDA Market Approval for Embozene(TM) Color-Advanced Microspheres Embolization Platform 3Health News:CeloNova BioSciences Receives FDA Market Approval for Embozene(TM) Color-Advanced Microspheres Embolization Platform 4
(Date:11/23/2009)...nker.comannouncesthatanewmarketresearchreportisava...ables-AWorldwideMarketReview ,, http://www.r...les---A-Worldwide-Market-Review.html#utm_source=pr...wire ,, Withincreaseinrangeofinfectiousdise...italfacilities,nonwovenshasemergedasagoldmineforro...
(Date:11/23/2009)...ightSciencesOncology,Inc.(LSO)todayannouncedtheele...ewlycreatedseatonitsboardofdirectors.Mr.Seddighisw...es,includingElekta,tomarketleadership. ,, "Thea...businessdevelopmenttotheboard,"saidLSO,sChairmanof...cer-therapybusinessdevelopment.Hehasoverseentheeme...
(Date:11/23/2009)...ndsResearchGroup,Inc.releasedWave2ofits LaunchTre...sesyndicatedmarketresearchprojecttrackingthelaunch...ixmonthsofproductavailability.Eachwaveofthereportp...gistsandqualitativeinformationfromasubsetof15.Ther...easonstouse,typicalpatienttypes,productperceptions...
Breaking Medicine Technology:Reportlinker Adds Medical Nonwoven Disposables - A Worldwide Market Review 2Reportlinker Adds Medical Nonwoven Disposables - A Worldwide Market Review 3Reportlinker Adds Medical Nonwoven Disposables - A Worldwide Market Review 4Reportlinker Adds Medical Nonwoven Disposables - A Worldwide Market Review 5Reportlinker Adds Medical Nonwoven Disposables - A Worldwide Market Review 6Reportlinker Adds Medical Nonwoven Disposables - A Worldwide Market Review 7Reportlinker Adds Medical Nonwoven Disposables - A Worldwide Market Review 8Light Sciences Oncology Elects Akbar Seddigh, Chairman of Elekta AB to Its Board of Directors 2Reported Use of AMAG's Feraheme (ferumoxytol) Continues To Be Low, But a Number of Nephrologists Are 'On the Verge' of Use 2Orexigen 28R 29 Therapeutics Announces In Licensing of Key Patents to Further Strengthen its Intellectual Property Estate for Contrave 28R 29 48582 1Orexigen 28R 29 Therapeutics Announces In Licensing of Key Patents to Further Strengthen its Intellectual Property Estate for Contrave 28R 29 48582 2Orexigen 28R 29 Therapeutics Announces In Licensing of Key Patents to Further Strengthen its Intellectual Property Estate for Contrave 28R 29 48582 3Moving Beyond the Mysteries of Disruption Reporting 48579 1Moving Beyond the Mysteries of Disruption Reporting 48579 2PharmaSURVEYORs Advanced Drug Safety Service Connects to Microsoft HealthVault 48576 1PharmaSURVEYORs Advanced Drug Safety Service Connects to Microsoft HealthVault 48576 2
..., Germany, June 5, 2007 – This,year’s ...ng,in Chicago sees a wealth of promising new data ...ncer therapy Erbitux®,(cetuximab), further dem... of this agent in both first-line and subsequent,t...d squamous cell,carcinoma of the head and neck (SC...
... at Society of Nuclear Medicine Annual Meeting -, ...-,Immunomedics, Inc. , a biopharmaceutical company...eat cancer and other serious,diseases, today annou...h the Company,s humanized anti-MUC1 monoclonal ant...ium-90 (Y-90), in patients with,unresectable and m...
Other Medicine Technology:Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 2Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 3Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 4Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 5Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 6Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 7Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 8Immunomedics Reports Initial Clinical Results With Hpam4 For,Pancreatic Cancer Therapy 2Immunomedics Reports Initial Clinical Results With Hpam4 For,Pancreatic Cancer Therapy 3Immunomedics Reports Initial Clinical Results With Hpam4 For,Pancreatic Cancer Therapy 4Immunomedics Reports Initial Clinical Results With Hpam4 For,Pancreatic Cancer Therapy 5
Amylase (Colorimetric Method)
GGT Reagent
Calcium liquid Reagent
ALT (SGPT) Reagent Set (UV-Kinetic Method)
Medicine Products: